Published in Blood on May 06, 2013
The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nat Commun (2014) 1.90
Mutations of epigenetic regulatory genes are common in thymic carcinomas. Sci Rep (2014) 1.00
Targeting novel signaling pathways for resistant acute myeloid leukemia. Mol Genet Metab (2014) 0.94
Epigenetic Control of Stem Cell Potential during Homeostasis, Aging, and Disease. Cell Stem Cell (2015) 0.94
Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia. Blood (2015) 0.88
MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. Haematologica (2015) 0.85
DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy. PLoS One (2014) 0.85
Functional interdependence of BRD4 and DOT1L in MLL leukemia. Nat Struct Mol Biol (2016) 0.85
Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia. Exp Hematol (2014) 0.84
Perspectives and future directions for epigenetics in hematology. Blood (2013) 0.82
Structure-guided DOT1L probe optimization by label-free ligand displacement. ACS Chem Biol (2015) 0.81
MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. J Clin Invest (2016) 0.80
NF-κB: a coordinator for epigenetic regulation by MLL. Cancer Cell (2013) 0.79
Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention. Curr Opin Oncol (2015) 0.79
The mechanistic role of DNA methylation in myeloid leukemogenesis. Leukemia (2014) 0.79
Hypermethylation and down-regulation of DLEU2 in paediatric acute myeloid leukaemia independent of embedded tumour suppressor miR-15a/16-1. Mol Cancer (2014) 0.78
Epigenetics of hematopoiesis and hematological malignancies. Genes Dev (2016) 0.77
Loss of Dnmt3b accelerates MLL-AF9 leukemia progression. Leukemia (2016) 0.76
Aberrant epigenetic regulators control expansion of human CD34+ hematopoietic stem/progenitor cells. Front Genet (2013) 0.75
Emergence of heterogeneity in acute leukemias. Biol Direct (2016) 0.75
Epigenetic control of gene expression in leukemogenesis: Cooperation between wild type MLL and MLL fusion proteins. Mol Cell Oncol (2014) 0.75
Epigenetics in Normal and Malignant Hematopoiesis: An Overview and Update 2017. Cancer Sci (2017) 0.75
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Long noncoding RNA as modular scaffold of histone modification complexes. Science (2010) 15.23
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
A unique chromatin signature uncovers early developmental enhancers in humans. Nature (2010) 14.02
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature (2011) 9.71
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J (2003) 9.55
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature (2011) 8.29
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010) 7.96
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell (2008) 6.86
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell (2010) 6.72
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev (2007) 6.71
A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell (2010) 6.00
hDOT1L links histone methylation to leukemogenesis. Cell (2005) 5.83
Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol (2002) 5.53
Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet (2012) 5.42
Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell (2009) 5.26
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23
AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell (2010) 4.99
Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet (2010) 4.90
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A (2010) 4.52
Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell (2008) 4.44
Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell (2009) 4.43
Identification of high-copy disruptors of telomeric silencing in Saccharomyces cerevisiae. Genetics (1998) 4.42
The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science (2010) 4.37
JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells. Nature (2010) 4.35
Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell (2008) 4.20
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol (2012) 3.89
Jumonji modulates polycomb activity and self-renewal versus differentiation of stem cells. Cell (2009) 3.75
Dynamics and memory of heterochromatin in living cells. Cell (2012) 3.75
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 3.74
The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell (2005) 3.70
The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu Rev Biochem (2012) 3.61
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood (2007) 3.60
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther (2009) 3.56
A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell (2010) 3.47
Functional cooperation between HP1 and DNMT1 mediates gene silencing. Genes Dev (2007) 3.43
Global analysis of H3K4 methylation defines MLL family member targets and points to a role for MLL1-mediated H3K4 methylation in the regulation of transcriptional initiation by RNA polymerase II. Mol Cell Biol (2009) 3.26
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol (2012) 3.15
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A (2012) 3.03
The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood (2005) 2.99
Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS Genet (2012) 2.94
High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood (2008) 2.86
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood (2009) 2.57
Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature (2008) 2.51
The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell (2010) 2.50
Pro isomerization in MLL1 PHD3-bromo cassette connects H3K4me readout to CyP33 and HDAC-mediated repression. Cell (2010) 2.44
Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J (2003) 2.43
Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev (2008) 2.41
Readers of histone modifications. Cell Res (2011) 2.40
MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell (2010) 2.29
The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell (2012) 2.26
Histone demethylases in development and disease. Trends Cell Biol (2010) 2.25
Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol Cell (2010) 2.25
The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol (2001) 2.21
Polycomb protein Ezh1 promotes RNA polymerase II elongation. Mol Cell (2011) 2.18
Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood (2010) 2.15
Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers. Mol Cell (2011) 2.12
Definitive hematopoiesis requires the mixed-lineage leukemia gene. Dev Cell (2004) 2.09
A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc Natl Acad Sci U S A (2009) 2.06
Enhancer-associated H3K4 monomethylation by Trithorax-related, the Drosophila homolog of mammalian Mll3/Mll4. Genes Dev (2012) 2.04
CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell (2011) 2.01
Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood (2011) 1.99
Histone and DNA methylation defects at Hox genes in mice expressing a SET domain-truncated form of Mll. Proc Natl Acad Sci U S A (2006) 1.98
DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood (2011) 1.88
Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res (2010) 1.77
A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev (2012) 1.75
Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun (2012) 1.67
PRC2 directly methylates GATA4 and represses its transcriptional activity. Genes Dev (2012) 1.66
UTX, a histone H3-lysine 27 demethylase, acts as a critical switch to activate the cardiac developmental program. Dev Cell (2011) 1.66
Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells. Blood (2011) 1.66
β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell (2010) 1.65
Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia (2012) 1.64
Ezh1 is required for hematopoietic stem cell maintenance and prevents senescence-like cell cycle arrest. Cell Stem Cell (2012) 1.60
GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell (2010) 1.57
Methylation at lysine 4 of histone H3 in ecdysone-dependent development of Drosophila. Nature (2003) 1.57
Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood (2012) 1.56
Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci U S A (2012) 1.52
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood (2013) 1.46
The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia. Oncogene (2012) 1.46
Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia (2012) 1.36
Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood (2011) 1.32
Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev (2012) 1.26
Retracted Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat Commun (2012) 1.24
The PHD fingers of MLL block MLL fusion protein-mediated transformation. Blood (2008) 1.18
SET7/9 mediated methylation of non-histone proteins in mammalian cells. Epigenetics (2009) 1.16
Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription. J Mol Biol (2010) 1.16
Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways. Proc Natl Acad Sci U S A (2012) 1.14
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am J Hematol (2011) 1.09
Chromatin regulated interchange between polycomb repressive complex 2 (PRC2)-Ezh2 and PRC2-Ezh1 complexes controls myogenin activation in skeletal muscle cells. Epigenetics Chromatin (2011) 1.07
Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6. Blood (2010) 0.88
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell (2007) 12.33
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell (2006) 10.29
MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer (2007) 8.17
H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell (2011) 4.90
MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell (2011) 4.56
The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science (2010) 4.37
Chromatin-modifying enzymes as modulators of reprogramming. Nature (2012) 4.22
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell (2006) 3.93
HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood (2008) 3.12
Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell (2012) 2.89
AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell (2011) 2.77
Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood (2003) 2.35
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood (2007) 2.12
mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell (2012) 2.06
Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J (2005) 1.79
Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med (2013) 1.71
Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell (2009) 1.61
Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci U S A (2012) 1.52
Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood (2013) 1.46
In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell (2013) 1.42
Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood (2013) 1.38
Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood (2011) 1.32
Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood (2002) 1.30
Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev (2012) 1.26
Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Res (2011) 1.23
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood (2005) 1.20
The Stem Cell Discovery Engine: an integrated repository and analysis system for cancer stem cell comparisons. Nucleic Acids Res (2011) 1.18
Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood (2007) 1.18
Self-renewal related signaling in myeloid leukemia stem cells. Int J Hematol (2011) 1.17
Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol (2012) 1.15
miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. Blood (2009) 1.11
iCanPlot: visual exploration of high-throughput omics data using interactive Canvas plotting. PLoS One (2012) 1.10
Targeting epigenetic programs in MLL-rearranged leukemias. Hematology Am Soc Hematol Educ Program (2011) 1.08
Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Blood (2009) 1.05
A role for DOT1L in MLL-rearranged leukemias. Epigenomics (2011) 1.02
EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood (2012) 1.01
FLT3 as a therapeutic target in childhood acute leukemia. Curr Drug Targets (2007) 1.00
A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells. Cell Cycle (2010) 0.99
Targeting epigenetic regulators for cancer therapy. Ann N Y Acad Sci (2014) 0.95
NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant (2010) 0.95
Mixed lineage leukemia translocations and a leukemia stem cell program. Cancer Res (2007) 0.92
Cancer: inappropriate expression of stem cell programs? Cell Stem Cell (2008) 0.92
Leukemia stem cells and human acute lymphoblastic leukemia. Semin Hematol (2009) 0.92
Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia. Cancer Res (2005) 0.91
Linking miRNA regulation to BCR-ABL expression: the next dimension. Cancer Cell (2008) 0.91
The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML. J Exp Med (2012) 0.90
Gene expression profiling of leukemia stem cells. Methods Mol Biol (2009) 0.89
eXframe: reusable framework for storage, analysis and visualization of genomics experiments. BMC Bioinformatics (2011) 0.89
DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights. Future Oncol (2010) 0.87
Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis. Blood (2011) 0.86
Therapeutic implications of leukemia stem cell development. Clin Cancer Res (2007) 0.85
Erratum: Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data (2014) 0.83
Transformation from committed progenitor to leukemia stem cells. Ann N Y Acad Sci (2009) 0.83
HELP for AML: methylation profiling opens new avenues. Cancer Cell (2010) 0.83
Cancer stem cells in hematopoietic malignancies. Biol Blood Marrow Transplant (2008) 0.82
MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1. Clin Cancer Res (2010) 0.82
MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. J Clin Invest (2016) 0.80
Genome-wide SNP analysis in cancer: leukemia shows the way. Cancer Cell (2007) 0.80
Cancer: The flipside of Notch. Nature (2011) 0.79
MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. J Clin Invest (2016) 0.78
Genetics, epigenetics, and leukemia. N Engl J Med (2010) 0.78
Cancer Stem Cells in Hematopoietic Malignancies. Biol Blood Marrow Transplant (2008) 0.77
DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions. Mol Cell Biol (2013) 0.77
Erratum: Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med (2016) 0.76
Microarrays to identify new therapeutic strategies for cancer. Adv Cancer Res (2007) 0.76
Cancer. Can one cell influence cancer heterogeneity? Science (2012) 0.76
AACR Cancer Progress Report 2016. Clin Cancer Res (2016) 0.75
Stem cells: Dual response to Ras mutation. Nature (2013) 0.75
Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias. Br J Haematol (2005) 0.75
Erratum: PGBD5 promotes site-specific oncogenic mutations in human tumors. Nat Genet (2017) 0.75